163 related articles for article (PubMed ID: 26763193)
1. Synthesis of p-O-Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors.
Zhang L; Hou L; Sun W; Yu Z; Wang J; Gao H; Yang G
Drug Dev Res; 2016 Feb; 77(1):37-42. PubMed ID: 26763193
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
Hu M; Ye W; Li J; Zhong G; He G; Xu Q; Zhang Y
Chem Biol Drug Des; 2015 Mar; 85(3):280-9. PubMed ID: 24954438
[TBL] [Abstract][Full Text] [Related]
3. Acryloylamino-salicylanilides as EGFR PTK inhibitors.
Deng W; Guo Z; Guo Y; Feng Z; Jiang Y; Chu F
Bioorg Med Chem Lett; 2006 Jan; 16(2):469-72. PubMed ID: 16275081
[TBL] [Abstract][Full Text] [Related]
4. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
5. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase.
Zhu ZW; Shi L; Ruan XM; Yang Y; Li HQ; Xu SP; Zhu HL
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):37-45. PubMed ID: 20583855
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
[TBL] [Abstract][Full Text] [Related]
9. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
[TBL] [Abstract][Full Text] [Related]
12. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
14. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
15. Anion-triggered substituent-dependent conformational switching of salicylanilides. New hints for understanding the inhibitory mechanism of salicylanilides.
Guo L; Wang QL; Jiang QQ; Jiang QJ; Jiang YB
J Org Chem; 2007 Dec; 72(26):9947-53. PubMed ID: 18020364
[TBL] [Abstract][Full Text] [Related]
16. [Design, synthesis and antitumor activity of valproic acid salicylanilide esters].
Yuan M; Li JM; He GW; Zhong GC; Zhang YC
Yao Xue Xue Bao; 2013 Jun; 48(6):874-80. PubMed ID: 23984521
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
19. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Ibrahim DA; Abou El Ella DA; El-Motwally AM; Aly RM
Eur J Med Chem; 2015 Sep; 102():115-31. PubMed ID: 26256032
[TBL] [Abstract][Full Text] [Related]
20. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
